The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center

#90

Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.

Aim(s): To assess the value of FDG-PET on the prognosis of patients diagnosed with neuroendocrine tumors treated and followed-up in one center (Cliniques universitaires Saint-Luc, Brussels, Belgium).

Materials and methods: A retrospective analysis of all NET patients that benefited from an FDG-PET scan and Octreoscan® during their diagnostic work-up was made. Data regarding origin of the tumor, pathology characteristics (Ki-67 proliferation index) were analyzed according to FDG-PET positive or negative status. From 1999 until 12/2009, 46 patients (30 males), 55±15 years, had one FDG-PET scan; 43/46 also had an Octreoscan®. They consisted of 26 pancreatic tumors, nine midgut tumors, two duodenum, two main biliary tract, one lung, one stomach, one liver and three unknown primary NET. We looked at overall survival (OS) and time-to-therapeutic failure (TTF), which we defined as radiologic progression leading to a change in therapy. Survival and TTF curves were estimated according to the Kaplan-Meier method and compared with the Log-Rank test. A p-value <0.05 was considered significant.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Borbath I

Authors: Sacré F, Lhommel R, Lonneux M, Gigot J, Sempoux C,

Keywords: neuroendocrine tumors, PET-FDG, prognosis,

To read the full abstract, please log into your ENETS Member account.